Patent
DNA aptamers, method for inhibiting human galectin-1 and method of treating a mammal in need thereof
| العنوان: | DNA aptamers, method for inhibiting human galectin-1 and method of treating a mammal in need thereof |
|---|---|
| Patent Number: | 11649,460 |
| تاريخ النشر: | May 16, 2023 |
| Appl. No: | 16/825284 |
| Application Filed: | March 20, 2020 |
| مستخلص: | DNA aptamers that recognize the human galectin-1 hGal1 with a very high degree of binding affinity and specificity, and inhibit hGal1-induced hemagglutination, besides presenting antiproliferative effects in seven human solid tumor cell lines are disclosed. The cytotoxicity tests demonstrated that, among 41 sequences tested, four of them (SEQ ID NO.: 04, SEQ ID NO.: 09, SEQ ID NO.:10 and, SEQ ID NO.:12) have the best capacity of inhibiting the cell growth in tumor cell. Additionally, the aptamers developed in the present invention will be used, for example, in the treatment of disorders related to the binding of human galectin-1 to a ligand in a mammal, wherein said disorder is selected from the group consisting of inflammation, fibrosis, septic shock, cancer, autoimmune diseases, metabolic disorders, heart disease, heart failure, pathological angiogenesis, and eye diseases, mainly cancer. |
| Inventors: | Peinado Pereira, Joao Francisco (Ribeirao Preto, BR); Pereira Pola, Daniel (Rio de Janeiro, BR) |
| Assignees: | Peinado Pereira, Joao Francisco (Ribeirao Preto, BR), Pereira Pola, Daniel (Rio de Janeiro, BR) |
| Claim: | 1. Aptamers of nucleic acid comprising formula (1) [table included] formula (1) (SEQ ID NO: 46) wherein: Xan 1 , Xan 6 , Xan 7 , Xan 8 , Xan 9 , Xan 10 , Xan 11 , Xan 12 , Xan 16 , Xan 17 , Xan 18 , Xan 26 , Xan 28 , Xan 29 , Xan32, Xan 34 , Xan 35 , Xan 36 , Xan 40 , Xan 41 , Xan 42 , Xan 48 , Xan 49 , Xan 50 , Xan 51 and Xan 52 are A, T, C, G or absent; Xan 2 , Xan 3 , Xan 4 , Xan 5 , Xan 13 , Xan 14 , Xan 15 , Xan 19 , Xan 20 , Xan 21 , Xan 22 , Xan 23 , Xan 24 , Xan 25 , Xan 27 , Xan 30 , Xan 31 , Xan 33 , Xan 37 , Xan 38 , Xan 39 , Xan 43 , Xan 44 and Xan 45 are A, T, C, G; Xan 46 is A, T, C or absent; and Xan 47 is T, C, G or absent, wherein the aptamers are chemically modified or not. |
| Claim: | 2. Aptamers according to claim 1 , wherein the sequence of formula 1 is represented by any one of SEQ ID NO: 1 to SEQ ID NO: 20 or variants thereof with the same or highly similar tertiary structure that bind to the amino acid sequence SEQ ID NO. 42. |
| Claim: | 3. Aptamers according to claim 1 , wherein the aptamers inhibit the binding of human Galectin-1 to a ligand in a human, and or inhibiting the human Galectin-1 dimer formation, and/or causing the dissociation of human Galectin-1 dimeric form. |
| Claim: | 4. A method for treating a disorder relating to the binding of human galectin-1 to a ligand in a human, wherein said disorder is cancer, the method comprising administering the aptamers according to claim 1 . |
| Claim: | 5. The method according to claim 4 , wherein the pathological angiogenesis is neovascularization related to cancer. |
| Claim: | 6. The method according to claim 4 , wherein the cancer is selected from the group consisting of ovarian cancer, squamous cell carcinoma, a cancer of the digestive system, stomach cancer, liver cancer, colon cancer, a cancer of the thyroid, a cancer of the endometrium, adenocarcinoma of the endometrium, uterine cancer, uterine adenocarcinoma, a uterine smooth muscle tumor, breast cancer, prostate cancer, bladder cancer, a head cancer, a neck cancer, a glioma, a kidney cancer, pancreatic cancer, pancreatic ductal adenocarcinoma, nonsmall-cell lung cancer, and melanoma. |
| Claim: | 7. A method for inhibiting human Galectin-1, wherein the method comprises contacting a human cancer cell with an effective amount of a galectin-1-targeting compound comprising the aptamers according to claim 1 . |
| Claim: | 8. The method of claim 7 , wherein said aptamers have an affinity for the hydrophobic dimerization interface of galectin-1. |
| Claim: | 9. The method of claim 7 , wherein the method inhibits growth of the human cancer cell, proliferation of the human cancer cell, and/or inhibits tumor metastasis. |
| Claim: | 10. The method of claim 7 , wherein the method comprises the association of the galectin-1 targeting compound with chemotherapy drugs. |
| Claim: | 11. A method for treating cancer in a human in need thereof comprising administering a therapeutically effective amount of aptamers according to claim 1 . |
| Claim: | 12. Aptamers of nucleic acid comprising formula (2) [table included] formula (2) (SEQ ID NO: 47) wherein: Xan 1 and Xan 45 are C or is absent; Xan 2 , Xan 14 , Xan 17 , Xan 27 , Xan 30 , Xan 34 , Xan 36 and Xan 48 are A, C or G; Xan 3 , Xan 4 , Xan 9 , Xan 10 , Xan 16 , Xan 25 , Xan 33 and Xan 40 are A or C; Xan 5 , Xan 7 , Xan 20 , Xan 22 , Xan 32 , Xan 37 and Xan 38 are A, C or T; Xan 6 , Xan 8 , Xan 11 , Xan 29 , Xan 41 and Xan 47 are A or G; Xan 12 , Xan 24 , Xan 31 and Xan 46 are A, G or T; Xan 15 , Xan 21 , Xan 23 and Xan 35 are C or G; Xan 18 and Xan 43 are G or T; Xan 19 , Xan 39 and Xan 44 are A or T; Xan 26 and Xan 42 are C, G or T; Xan 28 is C or T, wherein the aptamers are chemically modified or not. |
| Claim: | 13. Aptamers according to claim 12 , wherein the sequence of formula 2 is represented by any one of SEQ ID NO: 4, 9, 10 and 12 or variants thereof with the same or highly similar tertiary structure that bind to the amino acid sequence SEQ ID NO. 42. |
| Claim: | 14. Aptamers according to claim 12 , wherein the aptamers inhibit the binding of human Galectin-1 to a ligand in a human; inhibit the human Galectin-1 dimer formation; and/or cause the dissociation of human Galectin-1 dimeric form. |
| Claim: | 15. A method for treating a disorder relating to the binding of human galectin-1 to a ligand in a human, wherein said disorder is cancer, the method comprising administering the aptamers according to claim 12 . |
| Claim: | 16. The method according to claim 15 , wherein the pathological angiogenesis is neovascularization related to cancer. |
| Claim: | 17. The method according to claim 15 , wherein the cancer is selected from the group consisting of ovarian cancer, squamous cell carcinoma, a cancer of the digestive system, stomach cancer, liver cancer, colon cancer, a cancer of the thyroid, a cancer of the endometrium, adenocarcinoma of the endometrium, uterine cancer, uterine adenocarcinoma, a uterine smooth muscle tumor, breast cancer, prostate cancer, bladder cancer, a head cancer, a neck cancer, a glioma, a kidney cancer, pancreatic cancer, pancreatic ductal adenocarcinoma, nonsmall-cell lung cancer, and melanoma. |
| Claim: | 18. A method for inhibiting human Galectin-1, wherein the method comprises contacting a human cancer cell with an effective amount of a galectin-1-targeting compound comprising the aptamers according to claim 12 . |
| Claim: | 19. The method of claim 18 , wherein said aptamers have an affinity for the hydrophobic dimerization interface of galectin-1. |
| Claim: | 20. The method of claim 18 , wherein the method inhibits growth of the human cancer cell, proliferation of the human cancer cell, and/or inhibits tumor metastasis. |
| Claim: | 21. The method of claim 18 , wherein the method comprises the association of the galectin-1 targeting compound with chemotherapy drugs. |
| Claim: | 22. A method for treating cancer in a human in need thereof comprising administering a therapeutically effective amount of aptamers according to claim 12 . |
| Claim: | 23. Aptamers of nucleic acid comprising formula (3) [table included] formula (3) (SEQ ID NO: 48) wherein: Xan 1 , Xan 2 , Xan 5 , Xan 6 , Xan 15 , Xan 22 , Xan 23 , Xan 34 , Xan 35 , Xan 49 , Xan 50 and Xan 51 are A, T, C, G or absent; Xan 3 , Xan 4 , Xan 7 , Xan 8 , Xan 9 , Xan 10 , Xan 11 , Xan 12 , Xan 13 , Xan 14 , Xan 16 , Xan 17 , Xan 18 , Xan 19 , Xan 20 , Xan 24 , Xan 25 , Xan 26 , Xan 27 , Xan 28 , Xan 29 , Xan 30 , Xan 31 , Xan 32 , Xan 33 , Xan 36 , Xan 37 , Xan 38 , Xan 39 , Xan 40 , Xan 41 , Xan 42 , Xan 43 , Xan 44 , Xan 45 , Xan 46 and Xan 48 are A, T, C, G; Xan 21 is C, G or T; and Xan 47 is A, G or T, wherein the aptamers are chemically modified or not. |
| Claim: | 24. Aptamers according to claim 23 , wherein the sequence of formula 3 is represented by any one of SEQ ID NO: 21 to SEQ ID NO: 41 or variants thereof with the same or highly similar tertiary structure that bind to the amino acid sequence SEQ ID NO. 42. |
| Claim: | 25. Aptamers according to claim 23 , wherein the aptamers inhibit the binding of human Galectin-1 to a ligand; inhibit the human Galectin-1 dimer formation; and/or cause the dissociation of human Galectin-1 dimeric form. |
| Claim: | 26. A method for treating a disorder relating to the binding of human galectin-1 to a ligand in a human, wherein said disorder is cancer, the method comprising administering the aptamers according to claim 23 . |
| Claim: | 27. The method according to claim 26 , wherein the pathological angiogenesis is neovascularization related to cancer. |
| Claim: | 28. The method according to claim 26 , wherein the cancer is selected from the group consisting of ovarian cancer, squamous cell carcinoma, a cancer of the digestive system, stomach cancer, liver cancer, colon cancer, a cancer of the thyroid, a cancer of the endometrium, adenocarcinoma of the endometrium, uterine cancer, uterine adenocarcinoma, a uterine smooth muscle tumor, breast cancer, prostate cancer, bladder cancer, a head cancer, a neck cancer, a glioma, a kidney cancer, pancreatic cancer, pancreatic ductal adenocarcinoma, nonsmall-cell lung cancer, and melanoma. |
| Claim: | 29. A method for inhibiting human Galectin-1, wherein the method comprises contacting a human cancer cell with an effective amount of a galectin-1-targeting compound comprising the aptamers according to claim 23 . |
| Claim: | 30. The method of claim 29 , wherein said aptamers have an affinity for the hydrophobic dimerization interface of galectin-1. |
| Claim: | 31. The method of claim 29 , wherein the method inhibits growth of the human cancer cell, proliferation of the human cancer cell, and/or inhibits tumor metastasis. |
| Claim: | 32. The method of claim 29 , wherein the method comprises the association of the galectin-1 targeting compound with chemotherapy drugs. |
| Claim: | 33. A method for treating cancer in a human in need thereof comprising administering a therapeutically effective amount of aptamers according to claim 23 . |
| Claim: | 34. A nucleotide sequence being at least 80% or more, similar to a nucleotide sequence selected from SEQ ID NOs. 1 to 41 or variants thereof or highly similar to their tertiary structure that bind specifically to the amino acid sequence SEQ ID NO. 42 (hGal1), with an affinity (Kd) of less than 70 uM. |
| Patent References Cited: | 8981075 March 2015 Ikebukuro 10494634 December 2019 Sheffield et al. 20140121278 May 2014 Mayo 2014070214 May 2014 2014159669 October 2014 2017176767 October 2017 |
| Other References: | Sundblad et al. The Journal of Immunology 199:3721-3730 (Year: 2017). cited by examiner Shih et al., “A Novel Galectin-1 inhibitor Discovered through One-Bead-Two-Compounds Library Potentiates the Anti-tumor Effects of Paclitaxel in vivo”,American Association for Cancer Research Journal, 2017, pp. 1-14. cited by applicant Ingrassia et al.,“Anti-Galectin Compounds as Potential Anti-Cancer Drugs”,Current Medicinal Chemistry, 2006, vol. 13, No. 29, pp. 3513-3527. cited by applicant Dings et al.,“Antitumor Agent Calixarene 0118 Targets Human Galectin-1 as an Allosteric Inhibitor of Carbohydrate Binding”, J. Med. Chem., 2012, vol. 55, pp. 5121-5129. cited by applicant Blanchard et al., “Galectin-1 inhibitors and their potential therapeutic applications: a patent review”,Taylor & Francis Group, 2016, pp. 1-18. cited by applicant Wdowiak et al., “Galectin Targeted Therapy in Oncology: Current Knowledge and Perspectives”, Int. J. Mol. Sci., 2018, vol. 19, No. 210, pp. 1-21. cited by applicant Ito et al., “Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment”, Cancer Metastasis Rev, 2012, pp. 1-16. cited by applicant Salatino et al., “Galectin-1 as a potential therapeutic target in autoimmune disorders and cancer”, Expert Opin. Biol. Ther., 2008, vol. 8, No. 1, pp. 45-57. cited by applicant Koonce et al., “Galectin-1 Inhibitor OTX008 Induces Tumor Vessel Normalization and Tumor Growth Inhibition in Human Head and Neck Squamous Cell Carcinoma Models”, Int. J. Mol. Sci., 2017, vol. 18, No. 2671, pp. 1-9. cited by applicant Blanchard et al., “Galectin-3 inhibitors: a patent review (2008-present)”, Expert Opin. Ther. Patents, 2014, vol. 24, No. 10, pp. 1-13. cited by applicant Dahlqvist et al., “Stereo- and regioselective hydroboration of 1-exo-methylene pyranoses: discovery of aryltriazolylmethyl C-galactopyranosides as selective galectin-1 inhibitors”, Beilstein J. Org. Chem., 2019, vol. 15, pp. 1046-1060. cited by applicant Cousin et al., “The Role of Galectin-1 in Cancer Progression, and Synthetic Multivalent Systems for the Study of Galectin-1”, Int. J. Mol. Sci., 2016, vol. 17, No. 1566, pp. 1-22. cited by applicant |
| Primary Examiner: | Whiteman, Brian |
| Attorney, Agent or Firm: | Lucas & Mercanti, LLP |
| رقم الانضمام: | edspgr.11649460 |
| قاعدة البيانات: | USPTO Patent Grants |
| الوصف غير متاح. |